Darius Juškevičius

Author

Darius Juškevičius

Also Known As

D Juskevicius, D. Juskevicius, D., Juskevicius, Darius Juskevicius, Darius Juškevičius, Juskevicius, D., Juskevicius, Darius, Juškevičius, Darius

Publications

Citations

H-Index

Concepts

All Affiliations

University Hospital of Basel University of Basel Swiss Group For Clinical Cancer Research Kantonsspital Aarau Institute of Oncology Research

About

Darius Juškevičius is an author at University Hospital of Basel specializing in pathology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	299
2	Immunology	5	5	111
3	Cell Biology	4	4	51
4	Molecular Medicine	2	2	71
5	Health Sciences	1	1	15

Darius Juškevičius

Publications

758

Citations

H-Index

Page 1

	Year	Citations
Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis Darius Juškevičius, Thomas Lorber, Joël Gsponer, Leukemia Lymphoid NeoplasiaTumor HeterogeneityNext-generation SequencingGeneticsPathology	2016	108
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort Darius Juškevičius, David Jucker, Dirk Klingbiel, Journal of Hematology & Oncology	2017	84
Mutational landscape of B‐cell post‐transplant lymphoproliferative disorders Thomas Menter, Darius Juškevičius, Mary Alikian, British Journal of Haematology	2017	80
High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations Vincent Pillonel, Darius Juškevičius, Charlotte K.Y. Ng, Leukemia	2018	66
Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease Matthias S. Matter, Michel Bihl, Darius Juškevičius, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin GeneticsPathogenesisMap2k1 L115v MutationPathologyRosai-dorfman Disease	2017	56
Diagnostic Utility of the Germinal Center–associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms Thomas Menter, Anjes Gasser, Darius Juškevičius, Applied immunohistochemistry & molecular morphology GeneticsImmunologyPathologyImmunophenotypingTumor Biology	2014	41
High throughput sequencing reveals high specificity of <i>TNFAIP3</i> mutations in ocular adnexal marginal zone B‐cell lymphomas Visar Vela, Darius Juškevičius, M. Gerlach, Hematological Oncology	2020	34
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study Alexandar Tzankov, Nora Leu, Simone Muenst, Journal of Hematology & Oncology	2015	33
Selective haematological cancer eradication with preserved haematopoiesis Simon Garaudé, Romina Marone, Rosalba Lepore, Nature	2024	32
Clinical, Morphologic, Phenotypic, and Genetic Evidence of Cyclin D1-positive Diffuse Large B-cell Lymphomas With CYCLIN D1 Gene Rearrangements Darius Juškevičius, Christian Ruiz, Stephan Dirnhofer, The American Journal of Surgical Pathology Hematological MalignancyLymphoid NeoplasiaMantle Cell LymphomaCyclin D1Genetics	2014	28

Page 1